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Abstract 
Studies on the polymerization mode of Neisseria meningitidis serogroup X capsular polymerase 
CsxA  recently identified a truncated construct that can be immobilized and used for length  
controlled on-column production of oligosaccharides. 
Here we combined the use of a synthetic acceptor bearing an appendix for carrier protein 
conjugation and the on-column process to a novel chemo-enzymatic strategy. After protein coupling 
of the size optimized oligosaccharide produced by the one-pot elongation procedure, we obtained a 
more homogeneous glycoconjugate compared to the one previously described starting from the 
natural polysaccharide.  Mice immunized with the conjugated fully synthetic oligomer elicited 
functional antibodies comparable to controls immunized with the current benchmark MenX 
glycoconjugates prepared from the natural capsule polymer of or from fragments of it enzymatically 
elongated. 
This pathogen-free technology allows the fast total in vitro construction of predefined bacterial 
polysaccharide fragments. Compared to conventional synthetic protocols, the procedure is more 
expeditious and drastically reduces the number of purification steps to achieve the oligomers. 
Furthermore, the presence of a linker for conjugation in the synthetic acceptor minimizes 
manipulations on the enzymatically produced glycan prior to protein conjugation. This approach 
enriches the methods for fast construction of complex bacterial carbohydrates. 
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Introduction 
Neisseria meningitidis (Men) is a Gram-negative bacterium responsible for bacterial meningitis and 
sepsis. Of the 12 different serogroups, the most common pathogenic strains are serotypes A, B, C, 
W and Y. Over the last 10 years, outbreaks of MenX occurred in Niger1, Uganda, Kenya2, Togo and 
Burkina Faso3, and rising incidence was also reported in America, Europe4 and China5. Monovalent 
carbohydrate-based vaccines to combat MenC infections and multivalent formulations targeting 
MenACWY serogroups have been licensed6, and proven to be cost-effective preventive therapies7.  
Although Men is diffused worldwide, a large prevalence is particularly observed in a region of Sub-
Saharan Africa, the so called meningitis belt8. In major African epidemics, attack rates range from 
100 to 800 per 100,000 population, but individual communities have reported rates as high as 1%, 
caused almost entirely by serogroup A9. To decrease Men epidemics in Africa, in 2010 a MenA 
conjugate vaccine (MenAfriVac) was rolled out in a mass vaccination program in the meningitis 
belt10. While the introduction of MenAfriVac has substantially reduced the incidence of serogroup 
A infections, the occurrence of other serotypes, such as C, W and X still remains relevant11. 
Increasing concern has also been raised by possible serogroup displacement, already described for 
A and C Men serogroups in China12, 13. As a consequence, a clinical trial testing vaccination with a 
pentavalent MenACWXY Tetanus Toxoid-conjugate (including MenX) has been lately 
completed14. 
Additionally, over the last 5 years different reports have disclosed strategies for conjugation of 
MenX CPS related fragments. Micoli et al.15 identified proper bacterial growth conditions for the 
optimal production and release of MenX PS. A glycoconjugate vaccine was prepared by CPS 
hydrolysis with a final average degree of polymerization (avDP) of 15-20 repeating units, showing 
its effectiveness in protecting against MenX disease.  
As an alternative to the polysaccharide isolation from pathogen cultures, chemically synthesized 
MenX oligomers with a maximal length of DP4 have been tested after coupling to a carrier 
protein16,17,18. However, the size of the oligomers was not sufficient to induce a proper immune 
response. In contrast, in vitro production of the MenX polymer by use of the recombinant MenX 
polymerase CsxA and introduction of this polymer (CPSX) into the  established glycoconjugate 
production procedure, delivered a vaccine that in mouse immunization studies induced a robust 
immune response identical to the benchmark19. Importantly, in this earlier protocol the enzyme 
catalyzed synthesis of CPSX was started with acceptors obtained by hydrolysis of the natural 
polysaccharide. Similarly to the approach used for other meningococcal vaccines20, the polymer 
chains were then hydrolyzed, sized to a length of avDP10 and, after appropriate functionalization, 
conjugated to a carrier protein15, 21. 
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Figure 1. (A) Structure of the repeating unit of MenX capsule polysaccharide. (B) Proposed approach based 
on on-column elongation of a synthetic MenX trisaccharide acceptor16. TDS = thexyldimethylsilyl. Letters a-
b in structure 3 are used for NMR assignments. 
 
In the last decade, methods for accelerating the production of biologically relevant carbohydrates 
have encountered fast development22-25. The availability of in vitro prepared defined glycans is key 
for the production of glycoconjugates devoid of pathogenic contaminants, with higher standards for 
characterization and more robust correlation between structure and immune activity26. Approaches 
combining synthetic and enzymatic steps have also been successfully developed to get access to a 
large number of carbohydrates27. Despite chemo-enzymatic synthesis has found its major use for the 
synthesis of mammalian glycans28, 29, examples are also reported for the production of complex 
bacterial sugars from Group B Streptococcus, Neisseria meningitidis and Shighella flexneri30-32. In 
this context, the use of heterologous bacterial enzymes has been exploited for the challenging 
incorporation of 1,2-cis linkages and α-sialylation, since it offers indisputable advantages in the 
stereochemical control of the reaction compared to chemical methods. Bacterial enzymes have also 
been used to assemble mammalian glycans33. 
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Here we describe a chemo-enzymatic approach based on the enzyme catalyzed one-pot elongation 
of a short synthetic MenX trisaccharide acceptor, bearing a chemical appendix already in place for 
conjugation.  By use of a recently described distributive variant of the capsule polymerase CsxA34, 
we synthesized oligomers with predefined average length which were directly conjugated to the 
genetically detoxified diphtheria toxin CRM197. The enzyme was coupled to a solid-phase to 
facilitate downstream processing of the reaction mixture. The chemo-enzymatically made 
glycoconjugate was immunologically evaluated in comparison to a glycoconjugate prepared using a 
polysaccharide fraction isolated from bacterial culture. 
 
Results and Discussion 
Chemical synthesis of MenX trisaccharide acceptor 
MenX capsular polysaccharide consists of N-acetylglucosamine-4-phosphate residues held together 
by α-(1→4) phosphodiester bonds (Figure 1A). Taking in consideration that the elongation cascade 
of CsxA polymerization was commenced in a previous report from a short acceptor with avDP 
3.219, we chemically synthesized the CPSX trisaccharide acceptor 3 (Figure 1B), as previously 
reported16. Briefly, 2-azido-2-deoxy silyl glucoside 1 was prepared in multigram scale in 9 steps 
from D-glucosamine hydrochloride (18% overall yield), and converted in two steps into the α-
hydrogenphosphonate 2, which was employed as key building block (Figure 1B).16 Elongation of 
intermediate 2 was carried out by iteration of a two-steps sequence, comprising pivaloyl chloride-
mediated hydrogenphosphonate coupling followed by Zemplén de-O-acetylation, to eventually 
afford trisaccharide 3 after global deprotection. On the whole acceptor 3 was obtained in 18 steps 
from D-glucosamine hydrochloride with a 0.3% overall yield, without taking into account that some 
intermediates could be recycled during the process16. NMR spectra of the trimer were in agreement 
with the published data16. The presence of a phosphodiester-linked amino propyl linker provides a 
chemical handle for coupling to a carrier protein15, 35.  
 
N-terminus CsxA mapping and on-column attachment 
CsxA used for the production of long CPSX is able to elongate short CPSX fragments with an avDP 
of ~319. CsxA works following two different elongation mechanisms: in the initial phase of the 
reaction, short DPs are elongated through a distributive mechanism, and the nascent chain is 
released after each transfer until an intermediate chain length of ~DP 18 is reached. Subsequently, 
intermediate length fragments (<DP18) bind to a separate binding site located in the C-terminus and 
are elongated in a processive manner, undergoing multiple rounds of monomer addition to reach the 
final polysaccharide length34. The interplay of the two mechanisms leads to skewed or even 
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separated product pools when using CxsA and prevents the generation of oligosaccharides suitable 
for the generation of a glycoconjugate vaccine34. 
Recently,  a truncated version of CsxA was generated (∆C98-CsxA) lacking the C-terminal binding 
site and thus allowing tailored synthesis of oligosaccharides with a length suitable for 
glycoconjugate synthesis34. While ∆C98-CsxA was shown to elongate DP>2, it had not been 
investigated if the missing C-terminus changed the overall binding pattern of the oligosaccharide 
acceptors. Consequently, we first analyzed the binding of short acceptors (avDP6.5) to wild type 
CsxA in comparison to ∆C98-CsxA.  
Saturation Transfer Difference (STD) NMR experiments were undertaken in order to qualitatively 
map the average positions of the MenX oligomers closer to binding pockets of the two constructs. 
An evaluation of the STDD-NMR spectrum (STD-NMR with blank subtraction) of the complex 
formed by CsxA and  the avDP of 6.5 fragments exhibited the strongest signal enhancement for H-
1, H-2 and H-4, followed by H-5 and the NHAc moiety and, with minor intensity, H-3 and H-6 
(Figure 2A). This suggests that the attack of the GlcNAc-UDP donor to the hydroxyl at position 4 
might occur from the bottom face of the oligomer. Most importantly, the same pattern of signals 
was observed between ∆C98-CsxA  and the avDP6.5 mixture,  with the only difference that the 
STD-NMR intensity was lower if compared to full-length CsxA, indicating  a weaker binding to the 
tested oligomers, as expected for a distributive enzyme. 
Following our main purpose to use the synthetic CPSX trimer as priming oligosaccharide for the 
enzymatic elongation, the interaction between this molecule and both CsxA constructs was mapped 
(Figure 2B). Again, the STD-NMR intensity in the presence of ∆C98-CsxA was lower, but the 
binding pattern was comparable to CsxA and, most importantly, in good agreement to the overall 
binding epitope of the natural avDP6.5. As anticipated, no STD-NMR signal was recorded for the 
linker, demonstrating that it does not interact with the enzyme in a specific way. Interestingly, both 
constructs have contact to H-1a and H-1b,c, demonstrating that CsxA is able to accommodate the 
synthetic trimer in its active site pocket and this interaction is not altered by the missing C-terminal 
binding site. Although we cannot exclude that a shorter fragment could bind to the enzyme, these 
findings confirmed that the synthetic trisaccharide was engaged by a C-terminally truncated CsxA 
construct with sufficient interaction for further elongation. A more in depth structural study of the 
interaction between the enzyme and different length oligomers will deserve further exploration. 
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 Figure 2. STDD-NMR spectra of the two MenX oligomers in complex with (A) full length CsxA and (B) 
truncated version ∆C98-CsxA at the specified molar ratio. Chemical shifts of the linker (at 3.4, 3.8, 2.9 and 
1.9 ppm) disappear at the STD NMR showing no engagement with the enzyme. 
 
Page 7 of 24
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 
 
Figure 3. (A) Elongation of DP2-10 acceptor by ∆N58∆C98-CsxA (left) and ∆C98-CsxA (right) at different 
donor/acceptor (d/a) ratios. (B) HPLC-AEC (214 nm) of synthetic DP3 elongated by ∆N58∆C98-CsxA at 
the indicated d/a ratios. (C) HPLC-AEC (280 nm) demonstrates that the donor sugar UDP-GlcNAc is 
completely converted to UMP in a representative trimer elongation  reaction. A reaction in the absence of 
acceptor was used as control. (D) Alcian blue/silver stained gel showing the reaction products after one 
column passage and two wash fractions in comparison to the marker avDP15. The gel shows an almost 
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overlapping profile between the targeted length and the formed oligomer after one column passage. (E) 
HPLC-AEC (214 nm) showing the reaction mixture after one column passage, two wash fractions and all 
fractions pooled (pool pre MonoQ) in comparison to avDP15 marker material. (F) Preparative AEC 
(MonoQ) was used to separate UMP from the pool. Calibration of the column using DPs of known size 
enabled the removal of DPs<9 to allow a maximal resemblance of the pooled fraction (pool post MonoQ) to 
the marker material.  (G) 1H NMR spectrum (400 MHz, D2O, 25°C) of the final product (pool post MonoQ) 
indicating an avDP of 12.  
 
MenX oligosaccharide production 
During the last years, on-column enzyme immobilization came out as a novel tool to reduce the 
high cost of enzyme production36. The main advantage of immobilized enzymes is the possibility to 
recover it at the end of the reaction for re-utilization and, consequently, an easier purification of the 
products from residual enzyme37. 
In a previous study, ∆N58∆C98-CsxA, a recombinant N- and C-terminally truncated CsxA 
construct  has already been proven suited for on-column immobilization and tailored synthesis of 
CPSX oligosaccharides34. ∆N58∆C98-CsxA was reported to be superior to ∆C98-CsxA with regard 
to expression level due to the missing, disordered N-terminal part of the protein, and was therefore 
chosen also in this study for the solid-phase elongation of the synthetic trimer 34. First, by STD-
NMR the binding of MenX fragments with ∆N58∆C98-CsxA was assessed to be over imposable 
with that of  ∆C98-CsxA (Figure S1, Supplemental information). Then, conditions for the 
elongation were set up on a natural acceptor with DP2-10, monitoring the reaction with the Alcian 
blue/silver stained PAGE analyses (Figure 3A)38. As previously shown for ∆C98-CsxA 34, the 
dispersity of the products generated at different donor to acceptor ratios (d/a) revealed a distributive 
elongation. Notably, ∆N58∆C98-CsxA allowed controlling the polymerization up to a size similar 
to the marker material containing oligomers with DP10-60.  
To determine optimal reaction conditions, ∆N58∆C98-CsxA reactions at varying ratios between 
UDP-GlcNAc (10 mM) and the trimer were performed and the products were analyzed by HPLC-
Anion Exchange Chromatography (AEC) (Figure 3B). The fact that the chain length of the 
produced polysaccharides decreases with decreasing UDP-GlcNAc/trimer ratio demonstrates that 
the linker does not impair the enzymes previously reported distributive elongation mechanism 
(Figure 3B). Moreover, the high efficacy of the reaction remains unaltered as shown by the 
complete conversion of UDP-GlcNAc to UMP (Figure 3C).   
In a next step, the ∆N58∆C98-CsxA construct was coupled to a HisTrap column via the C-terminal 
His6-tag as recently described (Figure 4)34. In our previous reports, we showed that 27 mg of 
dN58dC98-CsxA are purified from 1 L of expression culture19, and 62.5 µg or 250 µg of enzyme 
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are enough to convert 12.4 mL of reaction mixture (containing 10 mM of UDP-GlcNAc) into the 
final product in an overnight or 4 h reaction21, respectively.  In order to ensure the highest degree of 
conversion of the synthetic acceptor into the target oligomer in one column passage, we decided to 
load 100 mL of expression culture onto the column to transform 1.2 mL of reaction mixture into 
product, corresponding to more than a 100 fold excess of enzyme compared to the previous studies. 
The column was washed with binding buffer before the reaction mixture, containing the synthetic 
trimer and GlcNAc-UDP, was pumped through once (Figure 3C). According to the preceding tests 
(Figure 3B), a d/a ratio of ~15:1 was selected to target a size of avDP15. One passage through the 
column was sufficient to convert the acceptor into a product population similar to the target 
material, as verified by Alcian blue/silver stained PAGE (Figure 3D) and HPLC-AEC (Figure 3E). 
The material was purified by anion exchange chromatography (MonoQ) using a linear sodium 
chloride gradient34. To allow maximal resemblance to the target material typically used in 
glycoconjugate preparations20 (shown as marker in Figure 3E), only fractions containing DP>9 
(eluting between 320-550 mM of NaCl) were collected, dialyzed and further characterized (Figure 
3E-F). 
 
 
Figure 4. Reactions leading from trimer 3 to MenX glycoconjugate, which include on-column enzymatic 
elongation using GlcNAc-UDP as donor to give 4 and formation of an active ester for protein conjugation. 
 
The average length of the obtained oligomers was established using NMR analysis (Figure 3F and 
Figure S1 Supplemental information). The 1H NMR clearly showed a ratio of 1:11 between the H-1 
of the downstream end modified with the linker, appearing as a doublet of doublets at 5.45 ppm (J1,2 
= 1.4, 7.3 Hz ), and the H-1 of the other anomeric positions at 5.53 ppm, indicating that an avDP of 
12 was achieved with complete stereochemical control. In addition, the triplet at 3.13 ppm (J = 6.7 
Hz) assigned to the CH2NH2 of the linker unambiguously confirmed the incorporation of the 
synthetic acceptor in the enzymatically elongated oligomer (Figure 3G). The avDP was confirmed 
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in the 31P NMR spectrum of the obtained oligomer by the 1:11 ratio of the linker modified 
phosphodiester signal compared to the signals of the other interchain phosphodiesters (Figure S3). 
The discrepancy between the targeted avDP of 15 and the experimentally obtained avDP of 12 
indicates that the incorporation of GlcNAc-UDP into the oligomer proceeded with a yield  >80%, 
when only one passage on the column was applied. Based on the FPLC (Figure 3F)  profile the 
avDP 12 contained a distribution from 9 up to 20 repeating units. 
 
Conjugation to CRM197 
The presence of propyl-amine linker at the reducing end terminus renders the synthesized oligomer 
ready for conjugation through a reported procedure based on the active ester chemistry (Figure 4)39, 
40. Briefly, the oligomer was reacted with an excess of the N-hydroxysuccinimidyl adipate in 
DMSO:H2O containing triethylamine. The half ester, quantitatively obtained by precipitation with 
ethyl acetate and lyophilization, was then incubated overnight with the CRM197 at a 25:1 
saccharide/protein molar ratio.  
SDS-Page gel electrophoresis showed occurrence of conjugation with no detectable presence of 
unconjugated CRM197 (Figure 5A). Western blot analysis with anti MenX serum confirmed that the 
sugar was covalently linked to the protein.  
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 Figure 5. Characterization of the glycoconjugates: (A)  SDS-PAGE gel electrophoresis and Western-Blot 
analysis of the generated glycoconjugate in comparison to the two previously reported controls15, 21. (B) 
HPLC profile of the conjugates in size exclusion chromatography using absorption at 214 nm for detection. 
(C) Zoom of the H-1 signals of MenX oligosaccharide detected at 1H NMR before (400 MHz, D2O) and after 
conjugation (600 MHz, D2O). 
 
The formed glycoconjugate was purified by precipitation with ammonium sulfate, and characterized 
by microBCA and anion-exchange chromatography with pulsed amperometric detection (HPAEC-
PAD) analyses for quantification of the protein and saccharide components respectively. The final 
product was characterized by a 0.2 w/w saccharide to protein ratio, corresponding to a 3.1 mol/mol 
ratio, that was similar to the conjugates previously reported (Table 1)15, 21. The resulting conjugation 
efficiency of 12%, however, was lower than that achieved for the other MenX glycoconjugates (32-
34%), where a 10-12:1 saccharide:protein ratio was used at higher protein concentrations. At the 
applied protein concentration (~5 mg/mL) an efficiency ranging from 20 to 50% has been achieved 
for a number of glycans39, 40, and a glycosylation level similar to that obtained in this work has been 
reached also with lower (10-15:1) saccharide:protein ratios41. This suggests that scale up of the 
process under more concentrated conditions could improve the conjugation efficiency, minimizing 
the hydrolysis of the active ester which is in competition with the amide formation. 
The HPLC size exclusion chromatography profile of the purified glycoconjugate showed a peak at 
lower retention time than the unconjugated protein and with a more homogeneous profile in 
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comparison with our previously produced glycoconjugates, presumably as result of the more 
defined length selected for conjugation and lower occurrence of cross linking in the coupling step 
(Figure 5B).  
Moreover, 1H NMR of the final glycoconjugate showed 1:11 ratio between H-1 of the modified 
downstream end and the H-1 of the other anomeric positions, comparable to the one of the starting 
oligomer (Figure 5C and Figure S2 Supplemental information). This result indicated that there was 
no discrimination of oligosaccharide lengths during the conjugation reaction.  
 
Immunogenicity in mice 
To test the immunogenicity of the novel glycoconjugate vaccine, a mouse immunization study was 
carried out.  For this purpose, 1 µg saccharide dose was injected subcutaneously to eight female 
BALB/c mice (5-6 wk old) per group. Two positive controls were used in this experiment: a 
conjugate of MenX oligomers obtained from pathogenic bacteria (avDP15-20) and a conjugate 
prepared by enzymatic elongation of an acceptor produced from polysaccharide sizing (avDP10).  
Three immunizations were conducted with two week intervals, whereby the vaccines were 
formulated in phosphate buffered saline, pH 7.2, in the presence of aluminum phosphate as 
adjuvant. After the second and third vaccination, anti MenX IgG levels were measured by ELISA. 
CPSX-CRM197 glycoconjugate induced an immunogenic response comparable to the positive 
control with a significant booster effect after the third dose (Figure 6). 
 
 
Figure 6. (A) Anti-MenX IgG ELISA titers after the second and third dose of glycoconjugates, using CPSX 
for coating. Each dot represents an individual animal. The horizontal bars indicate the geometric mean titer 
and 95% confidence intervals. Statistical analysis between the indicated groups was performed according to 
Mann–Whitney test; SBA mediated by rabbit complement on pooled sera are shown in Table 2. 
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The functional activity of the elicited antibodies against MenX strain after the third immunization 
was evaluated determining the complement mediated bactericidal activity of the sera (Table 2)15. 
Rabbit serum was used as complement source. The pooled serum obtained after immunization with 
the chemo-enzymatically synthesized hapten showed a strong bactericidal activity (4096) against 
MenX. This bactericidal effect was comparable to the previously reported effects induced with the 
control glycoconjugates (8192 and 4096 for the glycoconjugate composed of polysaccharide from 
the pathogen and from in vitro polymerization of a pathogenic derived acceptor, respectively)15, 21. 
 
Conclusions 
Possible emergence of N. meningitidis serogroup X in Africa renders urgent the development of a 
conjugate vaccine. Methods for fast, pathogen free production of the vaccine are desirable. Here we 
describe a simple on-column procedure for the total synthesis of tailored and ready for coupling 
MenX fragments. Starting with a functionalized synthetic trisaccharide acceptor and GlcNAc-UDP 
as donor, the engineered capsule polymerase CsxA delivered oligomers with defined average 
length,  bearing at the downstream end a linker for conjugation to the carrier protein. 
By qualitative mapping of the interactions between the enzyme and the trisaccharide with STD-
NMR, we demonstrated that the short synthetic molecule was engaged by the N-terminal portion of 
the polymerase (∆C98-CsxA) similarly to a longer fragment obtained by sizing of the natural 
polymer. This portion is responsible for the distributive elongation mechanism. The optimized 
construct ∆N58∆C98-CsxA was then immobilized on-column and utilized for controlled elongation 
of the synthetic trisaccharide up to an avDP12. The produced oligomer was conjugated to the carrier 
protein CRM197 and tested in a mouse animal model resulting in strong production of bactericidal 
antibodies.  
The production of oligosaccharides composed of repeating units linked to each other through 
phosphodiester bonds for vaccine manufacturing has been shown feasible by chemical methods, 
such as polyconsensation via H-phosphonate intermediates42. These approaches present some 
important drawbacks: during the polycondensation reaction the formation of a linear product is in 
competition with cyclization43; the control of the stereochemistry is challenging when 1,2-cis bonds 
are formed16; finally the yield in the generation of phoshodiester bridges in some cases has been 
observed to decrease at the increase of the length44. 
The described technology in a simple and cost efficient way generates fully synthetic 
oligosaccharide antigens with controlled average length, thus avoiding the dangerous handling of 
pathogens. Compared to conventional synthetic protocols, the number of steps needed to obtain the 
oligomers in stereoselective manner are remarkably reduced. Furthermore, the presence of a linker 
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for conjugation in the synthetic acceptor minimizes the manipulations on the enzymatically 
produced glycan, such as hydrolysis, sizing and reductive amination steps, which are typically 
needed before coupling to a carrier protein. A variety of enzymes involved in bacterial capsular 
biosynthesis are known45, 46 and enzymatic in vitro elongation has been shown feasible for both 
homopolymers27, 47 and heteropolymers44 from different meningococcal serogroups. Therefore this 
approach is in principle applicable for the preparation of a number of glycans currently used to 
produce vaccines against bacteria and other pathogens.  
There are reports highlighting that small well-defined synthetic carbohydrate epitopes selected on 
the basis of their binding with protective antibodies are sufficient to elicit a robust immune response 
in an animal model24, 48, 49. In absence of structural information on the polysaccharide antigenic 
determinant, the described approach provided oligomers with a distribution optimized to induce a 
protective immune response comparable to longer structures and higher than the trimer and tetramer 
so far reported, indicating that relevant polysaccharide epitopes are fully covered. 
Along with one-pot/automated solid-phase/enzymatic syntheses, this on-column elongation chemo-
enzymatic synthesis enriches the methods for expeditious construction of complex bacterial 
carbohydrates. 
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Materials and methods 
 
STD-NMR experiments. NMR experiments were carried out on a Bruker 500 MHz NMR 
instrument equipped with a TBI cooled probe at controlled temperature (± 0.1 K). Data acquisition 
and processing were performed using TOPSPIN 1.3 and 3.1 softwares, respectively. Suppression of 
water signal was achieved by excitation sculpting (2 msec selective square pulse). Proton-Carbon 
Saccharides resonances were assigned collecting both 1D (1H and 13C) and 2D (COSY, HSQC) 
experiments, using standard pulse sequences. STD-NMR experiments were acquired with 96 scans 
over 96 accumulations and spectral width of 6000 Hz (12 ppm) at 298 K; a saturation transfer of 2/4 
sec was applied to enhance the saturation transfer effect, irradiating at a frequency of 8.0 and -2.0 
ppm (3 different spectra recorded for each sample). No differences were observed in the STD 
spectra irradiating at 8.0 or -2.0 ppm (4000 and -1000 Hz respectively) for all samples, confirming 
that the saturation transfer effect was not irradiation dependent. To avoid pitfalls in the 
interpretation of STD-NMR spectra, a negative control spectrum was always recorded in absence of 
enzyme (ligand and buffer) at the very same condition (concentration and pH) of the enzyme-
saccharide samples. The STD negative controls were always subtracted to the relative enzyme-
saccharide STD spectrum, obtaining the STDD experiments.  
For sample preparation, the enzymatic constructs were exchanged in the working buffer (Tris d-11 
50 mM, 20 mM MgCl2, in D2O at pH 8.0 +/- 0.1) through 2 mL Zeba Spin desalting column 
saturated with 3 cycles of working buffer, enzymes were finally eluted at the same starting 
concentration of 1 mg/mL. The 100% of recovery was assessed through microBCA 
spectrophotometric assay. Trisaccharide acceptor was dissolved in the working buffer too. Ligand 
(saccharides): enzyme ratios were set from 1:50 up to 1:100 mol/mol, depending on the sample. 
 
Chemo-enzymatic synthesis of MenX oligosaccharide.  
Small scale reactions (Fig. 3b) using ∆N58∆C98-CsxA were performed as previously described 34. 
Briefly, 50-200 nM of enzyme was incubated in 75 µL of reaction buffer (50 mM Tris pH 8.0, 20 
mM MgCl2, 1 mM DTT) in the presence of 10 mM UDP-GlcNAc and varying concentrations of the 
synthetic acceptor. Separation of the generated products by HPLC-AEC was performed on a 
Prominence UFLC-XR (Shimadzu) equipped with a CarboPac PA-100 column (2 x 250 mm, 
ThermoFisher) using an established method47. 
For solid-phase synthesis, ∆N58∆C98-CsxA was expressed in M15 (pREP4) over night at 15°C, as 
previously described34. 50-100 mL of expression culture were pelleted, lysed, coupled to a HisTrap 
(GE Healthcare) column and thoroughly washed with (i) binding buffer (50 mM Tris pH 8.0, 500 
mM NaCl, 35 mM imidazole, 1 mM DTT) and (ii) equilibration buffer (50 mM Tris pH 8.0, 1 mM 
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DTT) on an ÄKTA FPLC (GE Healthcare) until a stable base line was established. The HisTrap 
column was connected to a peristaltic pump P1 (GE Healthcare), and 1.2 mL of reaction mixture 
(50 mM Tris pH 8.0, 20 mM MgCl2, 10 mM UDP-GlcNAc, containing 1.2 mg of synthetic trimer at 
0.7 mM concentration) was pumped through with a flow-rate of 0.25-0.5 mL/min and fractions 
were collected. Samples were analyzed by Alcian blue/silver stained PAGE and HPLC-AEC as 
previously described34, 45 and saccharide containing fractions were pooledand further analyzed as 
described below to give the final avDP 12 oligomer (with a conversion > 80%).  
 
CRM197 conjugation of chemo-enzymatic obtained MenX oligosaccharide. A solution of di-N-
hydroxysuccinimidyl adipate (10 eq) and triethylamine (0.2 eq) in DMSO was added to oligomer 
(1.6 mg, 0.4 µmol). The reaction was stirred for 3h, than the product was precipitate at 0°C by 
adding ethyl acetate (9 volumes). The solid was washed 10 times with ethyl acetate (2 volumes 
each) and lyophilized. The activated sugar was conjugated to CRM197 (1 mg, 0.017 µmol) in 
sodium phosphate 100 mM at a protein concentration of 5 mg/ml. The glycoconjugate was dialyzed 
against 10 mM sodium phosphate pH 7.2 and then precipitated with ammonium sulfate providing 
450 µg of glycoconjugate (45%). 
 
Alcian blue/silver PAGE and SDS-PAGE gel electrophoresis. SDS-Page has been performed on 
pre-casted polyacrylamide gels (NuPAGE Invitrogen) that can be used with different 
polyacrylamide concentration, from 3-8% gradient to 7%. The electrophoretic runs have been 
performed in Tris-Acetate SDS running buffer (NuPAGE Invitrogen) loading 2.5-5µg of protein 
each sample, using the electrophoretic chamber with a voltage of 150V for about 40 minutes. After 
electrophoretic running, the gel has been washed in H2O for 3 times and then with dye comassie. 
 
Western Blot analysis. SDS-Page was run as described before. Gel was transferred on cellulose 
with iBlot gel transfer stacks nitrocellulose kit and washed 5 times with PBS 1x pH 7.2 + 0,05% 
tween and blocked with PBS 1x pH 7.2 + BSA 1%. Pooled serum from MenX-TT conjugate was 
used as primary antibody (1:500 dilution, 1h) followed by 5 washes with PBS + tween 0,05% 
buffer. Anti-mouse IgG alkaline phosphatase was used as secondary antibody (1:2000 dil., 30min) 
followed by 5 washes with PBS + tween 0.05% buffer. Western-Blot was finally developed with 
AP conjugate substrate kit (BIORAD). 
 
HPAEC-PAD analysis. As previously described50, standard samples of MenX PS at five increasing 
concentrations ranging between 0.2 and 8.0 µg/mL were prepared to build the calibration curve. 
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MenX samples were prepared targeting the calibration curve midpoint. The reference and analytical 
samples were prepared in 2 M trifluoroacetic acid, incubated at 100°C for 2.5h, followed by 30min 
at 4°C and finally quenched with 2 M sodium hydroxide. All analytical samples were filtered with 
0.45 µm Phenex-NY (Phenomenex) filters before analysis. HPAEC-PAD analysis was performed 
with a Dionex ICS-5000 equipped with a CarboPac PA1 column (4 × 250 mm; Dionex) coupled 
with a PA1 guard to column (4 × 50 mm; Dionex). Samples (50 µL injection volume) were run at 1 
mL/min, using isocratic elution with 14 mM NaOH, followed by a washing step with 0.5 M NaOH.  
In both HPAEC-PAD analyses, the effluent was monitored using an electrochemical detector in the 
pulse amperometric mode with a gold working electrode and an Ag/AgCl reference electrode. A 
quadruple-potential waveform for carbohydrates was applied. The resulting chromatographic data 
were processed using Chromeleon software 6.8 (Dionex). GlcNAc-4-phosphate51 concentration 
were determined and converted in µmol/mL to estimate the relative mol/mol ratio. 
 
Size Exclusion High Performance Liquid Chromatography (SEC-HPLC). SEC-HPLC has been 
performed on UltiMate 3000 HPLC system (Dionex part of Thermo Fisher Scientific) equipped 
with a PDA, RF2000 Fluorescence Detector and RI-101 Shodex Detector. Chromatography has 
been performed in 0.1 M NaSO4, 0.1 M NaPi, 5% CH3CN, pH 7.2 on TSK 3000SWXL (Tosoh 
Bioscience) analytical column at flow rate of 0.5 ml/min, with 50 µL of injection volume loading 
15-25 µg of sample in protein content. The resulting chromatographic data were processed using 
Chromeleon 6.8 software. 
 
Immunization of mice. Protocols were approved by the Italian Ministry of Health (Approval 
number n. 804/2015-PR). All mice were housed under specific pathogen-free conditions at the GSK 
Vaccines Animal Resource Center in compliance with the relevant guidelines (Italian Legislative 
Decree n 26/2014). Three groups of eight female BALB/c mice were immunized by subcutaneous 
injection of glycoconjugates at 1 µg dose in saccharide content using alum phosphate as an 
adjuvant. Mice received the vaccines at days 1, 14 and 28. Sera were bled at days 0, 27 and 42. 
 
ELISA of sera. Microtiter plates (96 wells, NUNC, Maxisorp) were coated with 100 µL of 5µg/mL 
of MenX CPS in Phosphate Buffered Saline (PBS) pH 8.2. Plates were incubated overnight at 2-
8°C, washed three times with PBST (0.05% Tween-20 in PBS pH 7.4) and saturated with 100 
µL/well of PBST-B (3% Bovine Serum Albumin-BSA in PBST) for 60 min at 37°C. The plates 
were then aspirated to remove the solution and re-washed three times with PBST. 200 µl/well of 
pre-diluted serum (1:25 for pre immune (negative control), 1:100-1:200 for a reference serum and 
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from 1:50 to 1:500 for test sera) was added in the first well of each column of the plate, while on the 
other wells 100 µl of TPBS has been dispensed. Eight two-fold serial dilutions along each column 
were then performed by transferring from well to well 100 µl of sera solutions. Following primary 
antibody dilution, plates were incubated for 2 h at 37° C. After three washes with TPBS, 100 µl/well 
TPBS solutions of secondary antibody alkaline phosphates conjugates (anti mouse IgG 1:10000, 
Sigma-Aldrich) were added, and the plates incubated 1 h at 37° C. Three more washes with TPBS 
were done, then 100 µl/well of a 1 mg/ml of p-NPP (Sigma) in a 0.5 M di-ethanolamine buffer pH 
9.6 was added. After 30 min of incubation at room temperature, plates were read at 405 nm using a 
Molecular Devices plate reader. Raw data acquisition has been performed by Softmax Pro 5.4. Sera 
titers were expressed as the reciprocal of sera dilution corresponding to a cut-off OD = 1. Each 
immunization group was represented as the geometrical mean (GMT) with 95% CI of the single 
mouse titers. The statistical and graphical analysis was performed by GraphPad Prism 6.0 software.  
 
Serum bactericidal assay (rSBA). A commercial lot of baby rabbit complement was used as 
source of active complement. N. meningitidis strain was grown overnight on chocolate agar plates at 
37°C in 5% CO2. Colonies were inoculated in Mueller-Hinton broth, containing 0.25% glucose to 
reach an OD600 of 0.05-0.08 and incubated at 37°C with shaking. When bacterial suspension 
reached OD600 of 0.25-0.27, bacteria were diluted in the assay buffer (Dulbecco's Phosphate-
Buffered Saline, DPBS) with MgCl2 and CaCl2 with 1% BSA) at the working dilution (ca. 10
4 
CFU/mL). The total volume in each well was 50µL with 25 µL of serial two-fold dilutions of the 
test serum, 12.5 µL of bacteria at the working dilution and 12.5 µL of baby rabbit complement. All 
sera to test were heat-inactivated for 30 minutes at 56°C. Negative controls included bacteria 
incubated, separately, with the complement serum without the test serum and with test sera and the 
heat-inactivated complement. Immediately after the addition of the baby rabbit complement, 
negative controls were plated on Mueller-Hinton agar plates (time 0). Plates were incubated for 1 
hour at 37°C, then each sample was spotted in duplicate on Mueller-Hinton agar plates (time 1). 
Agar plates were incubated overnight at 37°C and the colonies corresponding to time 0 and time 1 
(surviving bacteria) were counted. The serum bactericidal titer was defined as the serum dilution 
resulting in 50% decrease in colony forming units (CFU) per mL, after 60 min incubation of 
bacteria in the reaction mixture, compared to control CFU per mL at time 0. The reference strain 
meningococcal serotype X was Z9615. 
 
Supporting Information 
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The Supporting Information, including additional STD NMR spectra and characterization of the 
synthesized MenX oligomer, is available free of charge on the ACS Publications website. 
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